Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Reported trial records — page 25

644 records with the status reported.

Showing 0 records on this page

Records

644 documents · page 25 of 27

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
PRAM-T1D-PIVOTAL-ELDERLYprogramme recordPramlintidePhase 3ReportedRandomised, double-blind, placebo-controlled2002Very low
PRAM-T1D-PIVOTAL-OLEprogramme recordPramlintidePhase 3ReportedSingle-arm open-label2002Very low
TA1-HBV-1Thymosin alpha-1Phase 3ReportedRandomised, double-blind, active-controlled2001Moderate
TA1-HBV-1-REGIONAL-JPprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2001Very low
TA1-HBV-1-BODY-COMPprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2001Very low
TA1-HBV-1-QOLprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2001Very low
TA1-HBV-1-REGIONAL-CNprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled2001Very low
IPA-PH1-GHIpamorelinPhase 1ReportedPhase 1 ascending dose1998Low
TA1-VACCINE-ELDERLYThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Moderate
IPA-PH1-GH-ELDERLYprogramme recordIpamorelinPhase 1ReportedRandomised, double-blind, placebo-controlled1998Very low
TA1-VACCINE-ELDERLY-BODY-COMPprogramme recordThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Very low
IPA-PH1-GH-OLEprogramme recordIpamorelinPhase 1ReportedSingle-arm open-label1998Very low
TA1-VACCINE-ELDERLY-REGIONAL-JPprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled1998Very low
IPA-PH1-GH-ADHERENCEprogramme recordIpamorelinPhase 1ReportedObservational1998Very low
TA1-VACCINE-ELDERLY-REGIONAL-CNprogramme recordThymosin alpha-1Phase 3ReportedRandomised, double-blind, placebo-controlled1998Very low
IPA-PH1-GH-BIOMARKERprogramme recordIpamorelinPhase 1ReportedRandomised, double-blind, placebo-controlled1998Very low
TA1-VACCINE-ELDERLY-QOLprogramme recordThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Very low
IPA-PH1-GH-REGIONAL-CNprogramme recordIpamorelinPhase 3ReportedRandomised, double-blind, placebo-controlled1998Very low
HEX-PH2-ELDERLYHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Low
HEX-PH2-ELDERLY-REGIONAL-CNprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-QOLprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-BODY-COMPprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-REGIONAL-JPprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-ELDERLYprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low

page 25 of 27

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.